SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) December 11, 2003
ALEXION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 0-27756 | 13-3648318 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
352 Knotter Drive, Cheshire, CT | 06410 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (203) 272-2596
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press Release dated December 11, 2003.
Item 12. Results of Operations and Financial Condition
On December 11, 2003, the Company announced financial results for its first fiscal quarter ended October 31, 2003. A copy of the press release issued by the Company relating thereto is furnished herewith as Exhibit 99.1.
Limitation on Incorporation by Reference
In accordance with General Instruction B.6 of Form 8-K, the information in this report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC. | ||||
Date: December 11, 2003 |
By: | /S/ DAVID W. KEISER | ||
Name: | David W. Keiser | |||
Title: | President and Chief Operating Officer |
3